China-based cancer-therapy timing study retracted, fueling anti-China lobbying
TL;DR Summary
Nature Medicine has retracted a high-profile February paper detailing the results of a China-based trial on the timing of cancer therapy, a move that could energize anti-China policymakers and influence debates around immunotherapy timing.
- Retraction of high-profile paper on cancer drug timing could hand ammo to China hawks Endpoints News
- Nature retracts provocative PD-1 study that tied lung cancer survival to treatment timing Fierce Pharma
- Nature Medicine retracts Chinese lung cancer immunotherapy timing study 747 Live
- Paolo Tarantino: Nature Medicine Retracts Debated Study on Early Morning Immunotherapy Benefits Oncodaily
- Nature Retracts Cancer Study Suggesting Treatment Is Better Earlier in the Day MedPage Today
Reading Insights
Total Reads
1
Unique Readers
13
Time Saved
3 min
vs 3 min read
Condensed
94%
594 → 34 words
Want the full story? Read the original article
Read on Endpoints News